Contents
Insights · Sample Work · Case report writing
Case Report Writing Sample: Liver Cirrhosis
A portfolio piece, not clinical guidance. It shows how we build a case report to the CARE guideline, using an illustrative composite case rather than a real patient.
This is a writing sample. It shows how we structure a clinical case report to the CARE guideline, using an illustrative composite case rather than a real patient. It is not medical advice and not a patient information leaflet.
Please read first
This is a portfolio piece, not clinical guidance. The patient below is an illustrative composite created for this sample; no real patient is described, and no identifiable information appears. Nothing here should be used to make decisions about anyone’s care. If you are looking for information about your own health or a patient’s, speak to a clinician and work from the current guidelines cited at the end.
About this sample
Case reports are one of the things we write. They are deceptively hard: the clinical content has to be accurate, the structure has to satisfy a reporting guideline, the patient has to be unidentifiable, and the whole thing has to make a point a reader can take away.
This sample demonstrates the first three. It follows the CARE guideline, the consensus reporting standard for case reports, which has 13 checklist items10. In a real submission, item 13 — informed consent — would be satisfied by written consent from the patient, who under ICMJE’s requirement must be shown the manuscript before publication11. No consent statement appears below because there is no patient.
The case
Patient information
A man in his late fifties presented to a general medical clinic with four weeks of increasing abdominal distension and ankle swelling. He had a ten-year history of type 2 diabetes and had been told some years earlier that blood tests showed “a fatty liver”. He drank little alcohol. He had not previously been admitted to hospital for liver disease.
Clinical findings
He was alert and orientated, with no asterixis. Abdominal examination showed shifting dullness consistent with moderate ascites. There was bilateral pitting oedema to mid-shin. Spider naevi were present on the upper chest. He was not jaundiced.
Timeline
- Ten years before presentation: type 2 diabetes diagnosed.
- Six years before: incidental finding of hepatic steatosis on abdominal ultrasound; no follow-up arranged.
- Four weeks before: onset of abdominal distension and ankle swelling.
- Day 0: clinic presentation, as above.
- Day 3: investigations completed; diagnosis established.
- Week 6: review; ascites controlled, surveillance arranged.
Diagnostic assessment
Blood tests showed a low platelet count and a mildly raised bilirubin with a normal INR9. Abdominal ultrasound showed a nodular liver contour, splenomegaly and moderate ascites. Transient elastography returned a liver stiffness measurement well above the threshold at which advanced chronic liver disease is highly likely3. Viral hepatitis serology and an autoimmune screen were negative. A diagnosis of cirrhosis secondary to metabolic dysfunction–associated steatotic liver disease was made.
Liver biopsy was not performed. Current guidance positions non-invasive tests as the routine first-line route while biopsy remains the reference standard, reserved for diagnostic uncertainty or trial enrolment3 — and here the non-invasive picture was consistent.
Therapeutic intervention
He was started on diuretic therapy with dietary sodium restriction, with weight and renal function monitored4. Diabetes management was intensified and weight loss supported. An upper gastrointestinal endoscopy was arranged for variceal screening6, and six-monthly hepatocellular carcinoma surveillance was initiated5.
Follow-up and outcomes
At six weeks the ascites had largely resolved and the peripheral oedema settled. He remained free of encephalopathy. He was entered into a structured follow-up programme covering diabetes, weight, variceal surveillance and six-monthly imaging.
Patient perspective
In a real case report this section would carry the patient’s own account, in their words, where they wish to give one. It is a CARE item and one of the most frequently omitted10.
Discussion
The teaching point is the one the timeline makes visible: an incidental finding of hepatic steatosis six years before presentation, with no follow-up arranged, in a patient who already had the metabolic risk factor that defines the condition. The first clinical contact with his liver disease was a decompensating event.
This case also illustrates a classification point that is easy to get wrong. The appearance of clinically evident ascites marks the transition from compensated to decompensated cirrhosis. Baveno VIII defines the compensated state as “Compensated cirrhosis/cACLD is defined by the absence of current or past decompensation of cirrhosis.”, and names the decompensating events as “clinically evident ascites (or hepatic hydrothorax) caused by portal hypertension, variceal bleeding” and “overt hepatic encephalopathy (HE)”. Ascites detectable only on imaging does not count — the consensus is explicit that “Minimal ascites or ascites detectable only by imaging” cannot be considered decompensation1.
The case is written as a single-patient report and makes no causal claim. One patient supports “this sequence is worth attention”, not “failure to follow up incidental steatosis causes decompensation”.
Why it is structured this way
The section order above is the CARE checklist order10, and it is not arbitrary. Patient information, clinical findings and timeline come before the diagnostic assessment so the reader meets the evidence before the conclusion. The timeline is a separate item because a narrative buries chronology, and chronology is often the point — as it is here.
The discussion comes after the outcome, and the patient perspective after the discussion, so the clinical account is complete before interpretation begins. Consent is the last item, which is a reporting position rather than a chronological one: in practice it is obtained first.
The clinical points this case turns on
Three things the writing has to get right, each a common error in submitted case reports:
Compensated and decompensated are defined states, and the complication list is a different list. Ascites, variceal bleeding and overt hepatic encephalopathy are the events that define first decompensation. Other serious complications are not on that list, which does not make them less serious:
Complications, and which define decompensation
| Complication | Note |
|---|---|
| Ascites | Fluid accumulation in the peritoneal cavity; the most common first decompensating event. |
| Variceal haemorrhage | Bleeding from portosystemic collaterals. A medical emergency, not a digestive complaint. |
| Hepatic encephalopathy | Neuropsychiatric dysfunction. Overt HE is a decompensating event; covert HE is not. |
| Hepatocellular carcinoma | The reason surveillance exists, and the reason it continues after the cause is treated. |
| Spontaneous bacterial peritonitis | Infection of ascitic fluid. A complication, but not one of the events that defines first decompensation. |
| Hepatorenal syndrome | Kidney failure arising from circulatory changes in advanced cirrhosis. As above — a complication, not a defining decompensating event. |
The decompensating events are those named by the Baveno VIII consensus1; the management of each is covered in the EASL decompensated-cirrhosis guideline2.
Reversibility needs stating carefully. Cirrhosis is not uniformly irreversible. Histological regression is documented — most robustly in hepatitis B on long-term antiviral therapy. A five-year study of tenofovir reported: “Of the 96 (28%) patients with cirrhosis (Ishak score 5 or 6) at baseline, 71 (74%) no longer had cirrhosis.”7 But regression is not the same as recompensation, and Baveno VIII says so directly: “Recompensation should not be confused with cirrhosis regression, which denotes histological regression from a cirrhotic to a non-cirrhotic liver architecture.”1 Portal hypertension can persist after successful treatment of the cause6, non-invasive tests cannot confirm regression3, and cancer surveillance continues regardless5,9. Writing “reversible” or “irreversible” flatly gets it wrong in either direction.
Nomenclature moves. NAFLD and NASH were renamed in 2023: the umbrella term is now steatotic liver disease, with “The name chosen to replace NAFLD was metabolic dysfunction–associated steatotic liver disease.” and “Persons with MASLD and steatohepatitis will be designated as metabolic dysfunction associated steatohepatitis (MASH).”8 A case report using the old terms dates itself immediately.
What we did on this piece
- Built the case to the CARE checklist, section by section, including the timeline and patient perspective items that are most often dropped.
- Checked every clinical statement against a current guideline, and found one of our own assumptions wrong in the process — biopsy has not been superseded, it has been displaced from first-line use, which is a different claim.
- Used current nomenclature, including the 2023 steatotic liver disease terms.
- Checked currency of every guideline cited, which surfaced that Baveno VIII (2026) now supersedes Baveno VII.
- Kept the claims inside what a single case supports.
- Made the composite status explicit in the title, the description and the body, so no reader can mistake a portfolio piece for clinical guidance.
Take-home message
This is a sample of case-report writing, not clinical guidance, and the patient is an illustrative composite. It follows the CARE guideline’s section order, which puts the evidence before the conclusion and separates the timeline out because chronology is frequently the teaching point. The clinical content is checked against current guidelines: ascites, variceal bleeding and overt hepatic encephalopathy are the events defining decompensation; cirrhosis regression is documented but is not the same as recompensation; and the 2023 nomenclature change to MASLD and MASH applies.
Questions we are asked
No. The case is an illustrative composite written for this sample, and no identifiable information appears. A real case report requires written informed consent from the patient, who under ICMJE’s requirement must be shown the manuscript before publication.
No. This is a writing sample, not clinical guidance or patient information. For clinical questions, speak to a clinician; the guidelines cited at the end of this page are the current authorities.
CARE, the consensus reporting standard for case reports, which has 13 checklist items. For surgical cases we use the SCARE extension, currently the 2023 version. Most journals now ask for a completed checklist at submission.
Written consent for publication is obtained before writing, and the patient is shown the manuscript. De-identification goes beyond names: dates, rare occupations, unusual feature combinations and image metadata can all identify someone, and ICMJE states that masking the eye region in photographs is inadequate protection.
Yes — that is the service this sample demonstrates. We work from de-identified clinical material, structure it to CARE, check the clinical content against current guidelines, and prepare the consent and checklist documentation journals require.
References and sources
- Baveno VIII Faculty. Baveno VIII — Advancing Consensus in Portal Hypertension. Journal of Hepatology. 2026, online ahead of print. doi:10.1016/j.jhep.2026.07.030 read 15 October 2026. View on Journal of HepatologyThe current consensus on portal hypertension, published online 19 August 2026. It supersedes Baveno VII (2022) and refines the criteria for recompensation. Volume and pages are not yet assigned.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology. 2018;69(2):406–460. doi:10.1016/j.jhep.2018.03.024 read 15 October 2026. View on Journal of HepatologyStill EASL’s current guideline on decompensated cirrhosis; no later revision was found.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis — 2021 update. Journal of Hepatology. 2021. read 15 October 2026. View on EASLThe source for what non-invasive tests can and cannot establish — including that they cannot confirm fibrosis regression.
- Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, Wong F, Kim WR. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014–1048. doi:10.1002/hep.31884 read 15 October 2026. View on HepatologyTreats ascites, spontaneous bacterial peritonitis and hepatorenal syndrome as one complication cluster.
- Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023. doi:10.1097/HEP.0000000000000466 read 15 October 2026. View on HepatologyThe source for the surveillance recommendation quoted on this page.
- Kaplan DE, Bosch J, Ripoll C, Thiele M, Fortune BE, Simonetto DA, Garcia-Tsao G. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024;79(5):1180–1211. doi:10.1097/HEP.0000000000000647 read 15 October 2026. View on HepatologyThe current AASLD guidance on portal hypertension and varices.
- Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. The Lancet. 2013. doi:10.1016/S0140-6736(12)61425-1 read 15 October 2026. View on The LancetThe strongest histological evidence that established cirrhosis can regress when the cause is treated.
- Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–1986. doi:10.1097/HEP.0000000000000520 read 15 October 2026. View on HepatologyThe 2023 renaming. NAFLD became MASLD and NASH became MASH, under the umbrella term steatotic liver disease. Material still using the old terms is out of date.
- Kwo PY. Hepatocellular Carcinoma Surveillance Following Hepatitis C Virus Cure. Gastroenterology & Hepatology. 2025;21(1):72–74. read 15 October 2026. View on Gastroenterology & HepatologyOn why surveillance continues after cure.
- Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; the CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. Journal of Medical Case Reports. 2013;7:223. doi:10.1186/1752-1947-7-223 read 15 October 2026. View on Journal of Medical Case ReportsThe reporting standard for case reports. Note 223 is an article number, not a page range. The statement was published simultaneously in seven journals; the other versions are listed on this page.
- International Committee of Medical Journal Editors. Protection of Research Participants. ICMJE Recommendations. read 15 October 2026. View on ICMJEThe source of the consent and anonymity requirements quoted on this page.
Pubrica AcademyWritten and maintained by the subject matter experts of Pubrica who do this work. Articles are revised when the standard underneath them moves, and each one carries the date it was last checked.
How Pubrica helps
Pubrica’s medical writing team prepares case reports from de-identified clinical material — structured to CARE, checked against current guidelines, with the consent and checklist documentation journals ask for.